Tableting and Chewable Bolus Manufacture for Ruminant Dose Regimes

In oral solid dosage production, Lianfan Powder is incorporated into directly compressed or wet-granulated formulations where the active loading is fixed between 5% and 60% w/w because lower active fractions create dose uniformity drift on rotary presses operating above 30 rpm, while higher active fractions can reduce compact tensile strength below the 1.0 MPa threshold needed for film coating. The process train begins with API sieving through a 0.5 mm mesh, followed by blending in a bin blender at 10–25 rpm for 15–30 min with microcrystalline cellulose, lactose monohydrate, croscarmellose sodium and magnesium stearate. Wet granulation, when required for poor-flowing API lots, uses a high-shear granulator with impeller speed 350–600 rpm; the granulate is dried in a fluid-bed dryer at inlet air temperature 60–70°C to a moisture endpoint of 2.0–4.5% w/w. Compression is performed on a rotary tablet press with compression force 8–30 kN and tablet weight 200–1000 mg for small-animal tablets, or 2–5 g for ruminant boluses. In-process control includes tablet hardness 40–120 N, friability below 1.0%, and weight variation under USP <905>. Dissolution testing is conducted according to USP <711> Apparatus II at 50 rpm in 900 mL of 0.1 N HCl where applicable to the product monograph. The governing standards are 21 CFR 211.110, 21 CFR 211.165, VICH GL2 for stability, and EU GMP Annex 4 for non-sterile veterinary dosage forms.

Field-scale tableting runs with Lianfan Powder have shown that batch-to-batch variation in API particle size above D90 150 µm produces segregation during hopper transfer and weight variation outside USP <905> when press speed exceeds 45 rpm. To restore acceptable flow, the incoming powder is pre-blended with fumed silica at 0.5–1.0% w/w or dry-milled through a 0.5 mm screen. Production is restricted to rooms not exceeding 50% RH because the powder sorbs moisture above 60% RH; direct compression lots showing loss-on-drying above 2.0% w/w are not processed without pre-drying in a tray dryer at 40–45°C for 4–6 h. Terminal product types include film-coated tablets, scored tablets, chewable boluses for cattle and sheep, and rapidly disintegrating oral tablets for companion animals.

What Terminal Sterilization Limits Apply to Injectable Solutions and Suspensions?

Injectable operations impose a different hierarchy of controls because sterility and endotoxin burden override powder-flow considerations. Lianfan Powder is dissolved or suspended in Water for Injection at a concentration of 1–20% w/v for solution products and 2–30% w/v for suspensions, with tonicity adjusted using sodium chloride 0.9% w/v and pH adjusted with 0.1 N HCl or 0.1 N NaOH. The compounding vessel is a jacketed stainless-steel tank with bottom-mounted homogenizer operated at 2900–3600 rpm for suspension deagglomeration; the target particle size after homogenization is D90 ≤ 10 µm to prevent syringe needle occlusion and to comply with USP <788> particulate matter limits. The solution is filtered through a 0.22 µm PVDF or polyethersulfone membrane, filled into depyrogenated Type I glass vials by a 8-head peristaltic pump filling machine, and sealed with chlorobutyl rubber stoppers. Where the active substance is thermostable, terminal steam sterilization is run at 121°C for a cycle delivering F0 ≥ 8; where thermolability is documented, aseptic filtration with subsequent lyophilization is selected. The governing standards include EU GMP Annex 1 for sterile products, 21 CFR 211.94 for containers, 21 CFR 211.113 for sterilization validation, USP <1> for injections, USP <85> for bacterial endotoxins, USP <788> for particulate matter, and EP 2.6.1 for sterility.

Production-scale failure modes in injectable filling are most frequently linked to stopper particulate release, peristaltic tubing spallation, and vial neck deformation during capping. Stopper washing in WFI at 80°C for 15 min reduces silicone particle contamination in subsequent USP <788> light obscuration testing. Batch-to-batch variation in crystal morphology can alter suspension sedimentation volume; a standardized jet-milling step at 6 bar grinding pressure and 25°C nitrogen flush restores D90 to ≤ 10 µm. The operational boundary is aqueous hold time: in-process solution holding beyond 8 h at 15–25°C increases hydrolytic degradation risk and is not permitted unless stability data in the registration dossier support a longer hold. Finished injectable product categories are single-dose vials, multi-dose vials, suspensions for injection, and diluent-mixed injectable formulations.

Unlike tablet compression, capsule filling operations place a different constraint on the same veterinary-grade API: flowability and dust generation, not dissolution or sterility, dominate process control. For hard gelatin or hydroxypropyl methylcellulose capsule formats, the API is typically preblended with lactose monohydrate, microcrystalline cellulose, and magnesium stearate at a total API load of 10–80% w/w; the exact load is fixed by the approved dose and the shell fill volume, commonly 0.30–0.50 mL for size 0 and size 1 capsules. The blend is milled through a 0.8 mm conical screen, mixed in a V-blender at 60–75% nominal fill volume, and transferred to a dosator or tamping pin capsule filler operating at 20,000–60,000 capsules/h. In-line checkweighing is conducted on composite samples every 15 min because fill weight RSD above 2.0% creates a USP <905> acceptance value higher than L1=15. Compliance with 21 CFR 211.110 requires blend uniformity sampling at no fewer than 10 locations; stability protocols for capsules typically include storage at 25°C/60% RH and 30°C/65% RH in aluminum blister or HDPE bottle closures. Dust release from dry powder filling below 0.5% moisture content is a production bottleneck on high-speed lines, requiring localized dust extraction and humidity control at 40–50% RH. The finished product categories are hard gelatin capsules, HPMC capsules, and dose-titration capsules for companion animal and equine use.

In drinking-water administration systems for swine and poultry, the same API is converted into water-soluble powder or oral solution concentrates. The formulation load is usually 1–50% w/w in lactose or dextrose carrier, with a dissolution endpoint ≤ 5 min in potable water at 20°C and 0.5% w/v reconstitution. Production uses a ribbon blender or ploughshare mixer at 25–50 rpm for 10–20 min after geometric dilution of the API with carrier; the blend is sifted through a 0.355 mm mesh and filled into low-moisture aluminum foil sachets or HDPE bottles. Equipment surfaces comply with 21 CFR 211.65 and cleaning validation under 21 CFR 211.67. Batch-to-batch fill mass variation is controlled below ±5% under EP 2.9.5, and residual solvent levels are monitored under VICH GL18. At API loadings above 30% w/w, electrostatic charging during sifting reduces flowability; pre-conditioning at 35–45% RH or addition of colloidal silicon dioxide at 0.5–1.0% w/w is required to avoid agglomeration on the sieve. The finished products are soluble powder sachets, oral solution concentrates for metering pump dilution, and drinking water suspension premixes for administration via proportional dosing systems.

When Medicated Premix Must Survive Pellet Conditioning Above 80°C

Medicated premix manufacture introduces the most severe thermal excursion among the non-sterile routes because the API must survive conditioner temperatures that reach 75–85°C for 20–45 s before pellet die compression. Lianfan Powder is first prepared as a concentrated premix at 1–20% w/w on a carrier such as calcium carbonate or wheat middlings, then diluted into complete feed to a final active concentration of 0.05–2.0% w/w. Mixing is performed in a ribbon mixer or paddle mixer at 20–40 rpm for 15–20 min; the blend is then conditioned with steam to 16–18% moisture and pressed through a ring die with compression ratio 1:4 to 1:6. Post-pellet cooling to below 5°C above ambient and moisture 12% must occur within 10–15 min to prevent residual heat from accelerating degradant formation. The governing framework is 21 CFR 225.1 for medicated feed cGMP, 21 CFR 558 for new animal drugs in feed, and VICH GL2 for stability data supporting the thermal excursion.

The production conflict is the simultaneous requirement for pellet durability and active potency: pellet durability above 95% usually demands higher conditioning temperature, but thermolabile APIs may show a degradation rate that effectively doubles with each 10°C rise in the conditioning set-point. In such cases, the validated process window is often no wider than ±5°C, and the pellet mill is equipped with jacket cooling and continuous NIR moisture monitoring to maintain exit temperature below 90°C. The thermal stress is characterized during validation by isothermal degradation studies at 70°C, 80°C and 90°C, and the data are reported in the VICH GL2 registration file. If the apparent activation energy derived from an Arrhenius plot is below 60 kJ/mol, the conditioner set-point is reduced by 5°C increments until the 90% lower confidence limit for potency remains within the approved specification at the end of shelf life. The same file must address moisture-mediated hydrolysis in post-pellet coolers, where water activity above 0.70 during the first 30 min of cooling can increase hydrolytic degradants beyond VICH GL3 reporting thresholds. Terminal product types are medicated feed pellets, crumbled feed, meal premix, and top-dress feed premix for swine and poultry operations.

Oral Granule and Pellet Extrusion-Spheronization for Dose-Flexible Veterinary Products

Extrusion-spheronization converts the API into spherical pellets with a narrow particle size distribution, typically between 0.6 mm and 1.2 mm, to improve dose titration and masking in oral administration. The API is loaded at 2–25% w/w with microcrystalline cellulose at 20–50% w/w, lactose monohydrate, and a binder such as hypromellose 2–4% w/w. The wet mass is extruded through a twin-screw extruder with L/D ratio 12:1–20:1 and die holes of 0.6–1.2 mm, then spheronized at 600–1000 rpm for 3–8 min. Drying is conducted in a fluid-bed dryer at inlet air 55–65°C to a final moisture of 2.0–4.0% w/w. The process is controlled under 21 CFR 211.65 for equipment design, 21 CFR 211.110 for in-process sampling, and USP <905> for content uniformity of the final pellet dose.

Spheronization yield losses on production batches with dilute API preblends below 5% w/w have been attributed to over-wetting and irregular pellet fracture. The corrective control is pH adjustment of the granulating fluid to 5.5–6.5 with citric acid/citrate buffer, which modulates binder hydration and reduces spheronizer dust formation. The main operational boundary is extruder torque: as granulation moisture drops below 45%, the torque can exceed 15 N·m on a 27 mm twin-screw extruder, causing screen blockage and spheronizer yield loss. The final pellets are screened through 1.4 mm and 0.5 mm sieves, and the usable fraction is filled into sachets or HDPE containers with desiccant to maintain moisture below 2.5% w/w. Terminal product types are oral granules for sprinkle administration, pellets for dose titration in small animals, and granular premix intermediates.

Lyophilized Vial Operations and Aqueous Vehicle Compatibility Limits

Lyophilized injectable production uses the API in aqueous solution only long enough to complete filling and freezing; residence time in the liquid state is the primary degradation vector. The pre-lyophilization solution is prepared at an API concentration of 2–30% w/v with mannitol or sucrose as bulking agents at 5–10% w/v and is filtered through a 0.22 µm membrane into depyrogenated Type I glass vials. Vials are loaded onto lyophilizer shelves pre-cooled to 5°C, frozen to -40°C at a ramp rate of 0.5–1.0°C/min, and subjected to primary drying at shelf temperature -20°C to -10°C and chamber pressure 50–200 µbar. Secondary drying is performed at 20–30°C until the cake moisture falls below 1.0% w/w. The governing standards are EU GMP Annex 1, 21 CFR 211.94 for container closure integrity, USP <1>, USP <85>, USP <788>, and EP 2.6.1.

Published data for the exact lyophilization cycle for Lianfan Powder with certain stabilizer matrices is limited; cycle design is therefore confirmed by differential scanning calorimetry and freeze-drying microscopy before scaling to production shelves. The same apparatus is fitted with comparative pressure measurement so that the chamber can be held at 50–200 µbar without exceeding the collapse temperature of the frozen matrix. If the collapse temperature is below -25°C, the primary drying shelf temperature is set no higher than -30°C and the ramp rate is slowed to 0.25°C/min. The operational boundary is aqueous hold time before freezing; holding the formulated solution for more than 4–6 h at 5–15°C is not recommended unless solution stability data under VICH GL2 demonstrate an acceptable degradant profile. Light-sensitive APIs in this format require amber vial glass and nitrogen overlay during filling at headspace oxygen below 2% v/v. Terminal product types are lyophilized vials for reconstitution, single-dose powder for injection, and veterinary emergency-use injectable vials.